SIRT3 silencing could produce an increment in ROS production and compromise the antioxidant response, thus, producing an enhancement of cisplatin-triggered apoptosis, which sensitizes breast cancer cells to cisplatin treatments (110). Here, SIRT3 is linked to breast carcinoma.